Condition
CAEBV
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 3 (1)
Trial Status
Unknown3
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07369739Phase 2Recruiting
Golidocitinib Combined With Selinexor for CAEBVD
NCT05347381Phase 3UnknownPrimary
Selinexol Combined With Dexamethasone in the Treatment of CAEBV
NCT05258136Not ApplicableUnknown
Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV
NCT04518982Phase 2UnknownPrimary
Sintilimab and Lenalidomide as a Treatment for CAEBV
Showing all 4 trials